Progress in human picornavirus research: New findings from the AIROPico consortium

Katja C. Wolthers, Petri Susi, Dirk Jochmans, Janne Koskinen, Olfert Landt, Neus Sanchez, Kaia Palm, Johan Neyts, Sarah J. Butcher

Research output: Contribution to journalReview articleAcademicpeer-review

3 Citations (Scopus)

Abstract

Several research groups in Europe are active on different aspects of human picornavirus research. The AIROPico (Academia-Industry R&D Opportunities for Picornaviruses) consortium combined the disciplines of pathogenesis, diagnostics and therapy development in order to fill the gaps in our understanding of how picornaviruses cause human disease and how to combat them. AIROPico was the first EU consortium dedicated to human picornavirus research and development, and has largely accelerated and improved R&D on picornavirus biology, diagnostics and therapy. In this article, we present the progress on pathogenesis, diagnostics and treatment strategy developments for human picornaviruses resulting from the structured, translational research approach of the AIROPico consortium. We here summarize new insights in protection against infection by maternal or cross-protective antibodies, the visualisation of interactions between virus and neutralizing antibodies by cryoEM structural imaging, and the outcomes from a picornavirus-infected human 3D organoid. Progress in molecular detection and a fast typing assay for rhinovirus species are presented, as well as the identification of new compounds potentially interesting as therapeutic compounds.

Original languageEnglish
Pages (from-to)100-107
Number of pages8
JournalAntiviral Research
Volume161
DOIs
Publication statusPublished - Jan 2019

Keywords

  • Antiviral therapy
  • Enterovirus
  • Pathogenesis
  • Picornavirus
  • Point of care (POC) diagnostics

Cite this